Home › Myelofibrosis › Alabama
Myelofibrosis clinical trials in Alabama
7 studies for Myelofibrosis are looking for participants at sites in Alabama.
Cities in Alabama
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- University of Alabama, Birmingham
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT04176198Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- University of Alabama At Birmingham, Birmingham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT07441694UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
- University of Alabama at Birmingham, Birmingham
RecruitingPhase 1
4 Weeks – 75 Years · All sexes · Updated Apr 13, 2026 · NCT06047886A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- University of Alabama Birmingham, Birmingham
RecruitingPhase 2
Ages 18 to 66 · All sexes · Updated Mar 17, 2026 · NCT06859424SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Birmingham
- Massive Bio SYNERGY-AI site, Mobile
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- UAB Hospital, Birmingham
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2025 · NCT06479135Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
- University of Alabama at Birmingham, Birmingham
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Feb 21, 2023 · NCT05280509From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.